Clonazepam in the Treatment of Panic Disorder With or Without Agoraphobia: A Dose-Response Study of Efficacy, Safety, and Discontinuance
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In this multicenter, parallel-group, placebo-controlled, fixed-dose study, the efficacy, safety, dosing characteristics, and discontinuation of clonazepam were analyzed in patients with panic disorder. Four hundred thirteen patients were randomly assigned to receive placebo or one of five fixed daily doses of clonazepam (0.5 mg, 1.0 mg, 2.0 mg, 3.0 mg, and 4.0 mg). After 3 weeks of dose escalation, the fixed dose was given for 6 weeks (the dose-maintenance phase) and then was tapered during a 7-week discontinuance phase. The completion rates for the dose-maintenance phase ranged from 59 to 85% for the clonazepam groups (74% for the placebo group). Efficacy measurements at the end of the dose-maintenance phase indicated clinical improvement in all treatment groups but with a clear differentiation of the four higher doses of clonazepam from the 0.5-mg dose and placebo. The minimum effective dosage, as determined by the Williams' test, was 1.0 mg daily. Dose-response analysis showed that daily dosages of 1.0 mg and higher were equally efficacious in reducing the number of panic attacks. All treatments were well tolerated. Somnolence and ataxia were reported more often by patients in the 3.0- and 4.0-mg groups; depression, dizziness, fatigue, and irritability, although not showing dose-relatedness, were reported by more patients taking clonazepam than placebo. During the discontinuance phase, most patients worsened from their condition at the end of the dose-maintenance phase but did not revert to that at baseline. In addition, with the tapering schedule chosen for this study, patients in all treatment groups tolerated the discontinuance of clonazepam. Daily doses of 1.0 to 2.0 mg of clonazepam offered the best balance of therapeutic benefit and tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Discontinuation of alprazolam treatment in panic patients
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.3.303 · Cited by 172
Research works printed but not linked: 17
- Noyes, 1984, Arch Gen Psychiatry, 41, 287, 10.1001/archpsyc.1984.01790140077009 · DOI · Paper page
- Charney, 1989, J Clin Psychiatry, 50, 418
- Spier, 1986, J Clin Psychiatry, 47, 238
- Pollack, 1986, J Clin Psychopharmacol, 6, 302, 10.1097/00004714-198610000-00010 · DOI · Paper page
- Herman, 1987, J Clin Psychopharmacol, 7, 175, 10.1097/00004714-198706000-00012 · DOI · Paper page
- Tesar, 1991, J Clin Psychiatry, 52, 69
- Beauclair, 1994, J Clin Psychopharmacol, 14, 111, 10.1097/00004714-199404000-00005 · DOI
- Dawson, 1984, Drugs, 27, 132, 10.2165/00003495-198427020-00002 · DOI · Paper page
- Noyes, 1991, Am J Psychiatry, 148, 517, 10.1176/ajp.148.4.517 · DOI
- Carter, 1995, J Clin Psychiatry, 56, 202
- Greenblatt, 1993, Arch Gen Psychiatry, 50, 715, 10.1001/archpsyc.1993.01820210049006 · DOI
- Williams, 1971, Biometrics, 27, 103, 10.2307/2528930 · DOI · Paper page
- Merz, 1994, Eur Psychiatry, 9, 123, 10.1017/S0924933800001085 · DOI
- Pollack, 1993, J Clin Psychopharmacol, 13, 257, 10.1097/00004714-199308000-00005 · DOI
- Lydiard, 1987, Am J Psychiatry, 144, 664, 10.1176/ajp.144.5.664 · DOI · Paper page
- Ballenger, 1993, J Clin Psychiatry, 54, 15
- Rickels, 1993, Arch Gen Psychiatry, 50, 61, 10.1001/archpsyc.1993.01820130067010 · DOI · Paper page
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Mitte, K. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.05.003 · Cited by 396
Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
“Rosenbaum [49] performed a 9week dose–response study (clonazepam dose escalated over 3 weeks to 0.”
BackgroundMethodTreatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Metadata
- Authors
- Rosenbaum, J. F., Moroz, G., & Bowden, C. L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1997-10
- Volume
- 17
- Issue
- 5
- Pages
- 390-400
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W67289524
- Cited by
- 75
- References
- 2
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clonazepam in the Treatment of Panic Disorder With or Without Agoraphobia: A Dose-Response Study of Efficacy, Safety, and Discontinuance. https://app.cochat.ai/papers/10.1097/00004714-199710000-00008
- The paper
- Rosenbaum, J. F., Moroz, G., & Bowden, C. L. (1997). Clonazepam in the Treatment of Panic Disorder With or Without Agoraphobia: A Dose-Response Study of Efficacy, Safety, and Discontinuance. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199710000-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.